Loading...
CSL Limited
CMXHF•PNK
Healthcare
Biotechnology
$148.56
$0.00(0.00%)
CSL Limited (CMXHF) Financial Performance & Statements
Review CSL Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-24.99%
↓ 24.99%
Operating Income Growth
-57.73%
↓ 57.73%
Net Income Growth
-20.81%
↓ 20.81%
Operating Cash Flow Growth
-27.27%
↓ 27.27%
Operating Margin
21.23%
↑ 21.23%
Gross Margin
51.16%
↑ 51.16%
Net Profit Margin
18.37%
↑ 18.37%
ROE
15.30%
↑ 15.30%
ROIC
9.81%
↑ 9.81%
CSL Limited (CMXHF) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for CSL Limited stock.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $1.66B | $2.33B | $15.18B | $1.81B |
| Short Term Investments | $157.48M | $0.00 | $0.00 | $3.60M |
| Cash & Short Term Investments | $1.66B | $2.33B | $15.18B | $1.81B |
| Net Receivables | $2.64B | $2.40B | $1.48B | $1.17B |
| Inventory | $5.96B | $8.21B | $6.30B | $3.78B |
| Other Current Assets | $506.00M | $340.00M | $208.10M | $214.40M |
| Total Current Assets | $10.77B | $13.91B | $23.94B | $7.39B |
| Property Plant & Equipment (Net) | $9.66B | $14.05B | $12.08B | $7.54B |
| Goodwill | $8.08B | $12.14B | $1.73B | $1.19B |
| Intangible Assets | $8.27B | $24.71B | $3.84B | $2.67B |
| Goodwill & Intangible Assets | $16.35B | $36.84B | $5.56B | $3.86B |
| Long Term Investments | $163.00M | $404.12M | $604.52M | $28.10M |
| Tax Assets | $911.00M | $1.36B | $752.56M | $529.53M |
| Other Non-Current Assets | $176.00M | -$12.13B | -$1.72B | -$1.18B |
| Total Non-Current Assets | $27.25B | $40.52B | $17.28B | $10.77B |
| Total Assets | $38.02B | $54.43B | $41.22B | $18.16B |
| Account Payables | $867.00M | $820.00M | $591.80M | $392.66M |
| Short Term Debt | $944.00M | $1.05B | $6.47B | $375.11M |
| Tax Payables | $175.71M | $444.68M | $191.23M | $313.02M |
| Deferred Revenue | $0.00 | $444.68M | $191.23M | $313.02M |
| Other Current Liabilities | $2.96B | $4.60B | $3.09B | $2.55B |
| Total Current Liabilities | $4.95B | $6.92B | $10.34B | $3.10B |
| Long Term Debt | $11.24B | $11.17B | $6.92B | $4.28B |
| Deferred Revenue Non-Current | $0.00 | $2.42B | $1.89B | $1.10B |
| Deferred Tax Liabilities Non-Current | $1.51B | $2.20B | $974.48M | $459.42M |
| Other Non-Current Liabilities | $918.00M | $8.10B | $2.10B | $2.29B |
| Total Non-Current Liabilities | $13.67B | $20.73B | $9.69B | $6.64B |
| Capital Lease Obligations | $1.66B | $2.42B | $1.89B | $1.10B |
| Total Liabilities | $18.62B | $27.65B | $20.02B | $9.74B |
| Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock | $371.39M | $517.00M | $483.80M | $0.00 |
| Retained Earnings | $16.01B | $21.96B | $19.64B | $12.25B |
| Accumulated Other Comprehensive Income/Loss | $1.35B | $1.75B | $1.56B | -$3.87B |
| Total Stockholders Equity | $17.33B | $23.72B | $21.20B | $8.38B |
| Total Equity | $19.37B | $26.78B | $21.20B | $8.38B |
| Total Liabilities & Stockholders Equity | $37.96B | $54.43B | $41.22B | $18.16B |
| Total Investments | $320.48M | $404.12M | $604.52M | $28.10M |
| Total Debt | $12.18B | $18.37B | $14.04B | $5.81B |
| Net Debt | $10.53B | $16.04B | -$1.13B | $4.00B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan